Turkey's BIO Startup 2022 begins to receive applications

28 March 2022
istanbul-big

Turkey’s first and only biotechnology-themed acceleration program BIO Startup has started to receive applications for 2022.

Supported by the country’s Association of Research-Based Pharmaceutical Companies (AIFD) and conducted by ReDis Innovation, the BIO Startup Program will continue to receive applications until March 31, 2022. Bio-entrepreneurs to take part in the Saveprogram will get the opportunity to attend the Bio-entrepreneurship Camp where they will receive thematic training and mentorship from experts of the industry.

Following the Bio-entrepreneurship Camp, entrepreneurs selected after their presentations at BIO Startup Demo Day, which will be attended by top managers and investment decision-makers of global companies, will have the chance to come together with actors of the international ecosystem via one-on-one meetings.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology